Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

FHS
March 11, 2024
12:55 pm

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.

GE Healthcare Launches Digital Tool for AFib

What You Should Know: – GE HealthCare launches CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to assist clinicians in visualizing longitudinal data relevant

August 25, 2023

ITP Drug Shows Benefit in Hospitalized COVID Patients

BOSTON — Fostamatinib (Tavalisse) added to standard care reduced the number of days on supplemental oxygen and improved clinical status in hospitalized patients with COVID-19,

October 14, 2023

Exclusive: GSK revamps its research strategy, building three teams to target specific disease spaces

GSK is shaking up the way it does research and created three unique teams zeroing in on vaccines and infectious diseases, respiratory and immunology, and

September 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.